Patents by Inventor Jason M. Cox

Jason M. Cox has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9708270
    Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: July 18, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mariappan Chelliah, Hong Dong Chu, Jason M. Cox, John S. Debenham, Keith Eagen, Ping Lan, Clare London, Michael A. Plotkin, Unmesh Shah, Christopher Joseph Sinz, Zhongxiang Sun, Henry M. Vaccaro, Srikanth Venkatraman
  • Patent number: 9505730
    Abstract: The present invention is directed to compounds of the Formula I as well as pharmaceutically acceptable salts thereof, that are potentially useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula I, to their possible use in the treatment of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula I.
    Type: Grant
    Filed: October 8, 2012
    Date of Patent: November 29, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Hong Shen, Jason M. Cox, Christine Yang, Zhicai Wu
  • Patent number: 9395311
    Abstract: A new technique which uses a pump-probe methodology to place a molecule into one or more excited rotational and/or vibrational states. By evaluating spectral changes due to at least one discrete frequency of pump photons a multi-dimensional characterization of the molecule's excited state energy level results. This multi-dimensional characterization typically involves evaluating the changes between excited and unexcited state measurements. The differential nature of the evaluation makes the technique self-referencing and solves problems common to many spectroscopic techniques. The multi-dimensionality of the technique provides high specificity and immunity to interferents. The preferred embodiments involve excitation by using photons suited to pumping the rotational states and evaluating the effects by probing the energy levels of one of more vibrational states.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: July 19, 2016
    Assignee: Kestrel Corporation
    Inventors: Eugene W. Butler, Timothy M. Stratman, Boyd V. Hunter, Paul Harrison, Jason M. Cox
  • Patent number: 9193717
    Abstract: The present invention is directed to compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, that are aldosterone receptor antagonists which might be useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula (I), to their possible use for the treatment of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula (I).
    Type: Grant
    Filed: October 8, 2012
    Date of Patent: November 24, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Hong Shen, Christine Yang, Jason M. Cox, Kun Liu
  • Publication number: 20150274672
    Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.
    Type: Application
    Filed: October 11, 2013
    Publication date: October 1, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Mariappan Chelliah, Hong Dong Chu, Jason M. Cox, John S. Debenham, Keith Eagen, Ping Lan, Clare London, Michael A. Plotkin, Unmesh Shah, Christopher Joseph Sinz, Zhongxiang Sun, Henry M. Vaccaro, Srikanth Venkatraman
  • Patent number: 9085568
    Abstract: The present invention is directed to compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof that are possible useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula (I), to their possible use for the treatment of the above mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula (I).
    Type: Grant
    Filed: October 8, 2012
    Date of Patent: July 21, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Hong Shen, Jason M. Cox, Hong Dong Chu
  • Publication number: 20150166490
    Abstract: The present invention is directed to compounds of the Formula I as well as pharmaceutically acceptable salts thereof, that are potentially useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula I, to their possible use in the treatment of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula I.
    Type: Application
    Filed: October 8, 2012
    Publication date: June 18, 2015
    Inventors: Hong Shen, Jason M. Cox, Christine Yang, Zhicai Wu
  • Publication number: 20150069258
    Abstract: A new technique which uses a pump-probe methodology to place a molecule into one or more excited rotational and/or vibrational states. By evaluating spectral changes due to at least one discrete frequency of pump photons a multi-dimensional characterization of the molecule's excited state energy level results. This multi-dimensional characterization typically involves evaluating the changes between excited and unexcited state measurements. The differential nature of the evaluation makes the technique self-referencing and solves problems common to many spectroscopic techniques. The multi-dimensionality of the technique provides high specificity and immunity to interferents. The preferred embodiments involve excitation by using photons suited to pumping the rotational states and evaluating the effects by probing the energy levels of one of more vibrational states.
    Type: Application
    Filed: August 29, 2014
    Publication date: March 12, 2015
    Applicant: Kestrel Corporation
    Inventors: Eugene W. Butler, Timothy M. Stratman, Boyd V. Hunter, Paul Harrison, Jason M. Cox
  • Publication number: 20140275133
    Abstract: The present invention is directed to compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof that are possible useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula (I), to their possible use for the treatment of the above mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula (I).
    Type: Application
    Filed: October 8, 2012
    Publication date: September 18, 2014
    Inventors: Hong Shen, Jason M. Cox, Hong Dong Chu
  • Publication number: 20140256723
    Abstract: The present invention is directed to compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof that are aldosterone receptor antagonists which might be useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula (I), to their possible use for the treatment of the above-mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula (I).
    Type: Application
    Filed: October 8, 2012
    Publication date: September 11, 2014
    Inventors: Hong Shen, Christine Yang, Jason M. Cox, Kun Liu
  • Patent number: 8716482
    Abstract: The present invention is directed to novel substituted aminopiperidines of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-ÏV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: May 6, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jason M. Cox, Tesfaye Biftu, Hong Dong Chu, Danqing Feng, Ann E. Weber
  • Patent number: 8653059
    Abstract: The present invention is directed to substituted six-membered heterocyclic compounds of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as obesity and diabetes, particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Grant
    Filed: August 18, 2008
    Date of Patent: February 18, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Tesfaye Biftu, Danqing Feng, Ann E. Weber, Jason M. Cox, Xiaoxia Qian, Jinyou Xu
  • Publication number: 20120149637
    Abstract: The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Application
    Filed: February 17, 2012
    Publication date: June 14, 2012
    Inventors: Tesfaye Biftu, Ping Chen, Jason M. Cox, Ann E. Weber
  • Publication number: 20120149683
    Abstract: The present invention is directed to novel substituted aminopiperidines of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-ÏV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Application
    Filed: September 15, 2010
    Publication date: June 14, 2012
    Inventors: Jason M. Cox, Tesfaye Biftu, Hong Dong Chu, Danqing Feng, Ann E. Weber
  • Patent number: 8143289
    Abstract: The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: March 27, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Tesfaye Biftu, Ping Chen, Jason M. Cox, Ann E. Weber
  • Publication number: 20110224195
    Abstract: The present invention is directed to substituted six-membered heterocyclic compounds of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as obesity and diabetes, particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Application
    Filed: August 18, 2008
    Publication date: September 15, 2011
    Inventors: Tesfaye Biftu, Danqing Feng, Ann E. Weber, Jason M. Cox, Xiaoxia Qian, Jinyou Xu
  • Patent number: 8017624
    Abstract: The present invention is directed to novel substituted fused aminopiperidines which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Grant
    Filed: August 22, 2006
    Date of Patent: September 13, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jason M. Cox, Scott D. Edmondson, Anthony Mastracchio
  • Patent number: 7943615
    Abstract: The present invention is directed to novel substituted fused aminopiperidines of structural formula (I) which are inhibitors of the dipeptidyl peptidase-4 enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-4 enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-4 enzyme is involved.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: May 17, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jason M. Cox, Scott D. Edmondson, Anthony Mastracchio
  • Patent number: 7910596
    Abstract: The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: March 22, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Tesfaye Biftu, Charles G Caldwell, Ann E. Weber, Ping P Chen, Xiaoxia Qian, Danqing Feng, Jason M. Cox
  • Patent number: 7884104
    Abstract: The present invention is directed to novel substituted aminopiperidines which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Grant
    Filed: September 27, 2005
    Date of Patent: February 8, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jason M. Cox, Scott D. Edmondson, Bart Harper, Ann E. Weber